News & Updates
Read the latest clinical, scientific, corporate, commercial, and event updates from TaiMed Biologics.
2025/12/17
TaiMed Biologics (4147) Announces First-Patient-In for Its World's First Long-Acting Dual Antibody HIV Therapy TMB-365/TMB-380 Phase 2b Trial, Marking a Key Acceleration Milestone in Global Long-Actin
2025/12/04
TaiMed Biologics (4147) Announces its Marketing Partner AcedrA BioPharmaceuticals Submitted registration dossier for the biological product Trogarzo® to the Saudi Food and Drug Authority(SFDA)
2025/12/01
TaiMed Biologics (4147) Signs Post-Approval Named Patient Program Supply Agreement with R-Pharm in Russia
2025/11/25
TaiMed Biologics (4147) Announces Its World-First Long-Acting Dual Antibody HIV Therapy TMB-365/TMB-380 Wins the 22nd National Innovation Award
2025/11/14
Dr. Jimmy Chang, CEO of TaiMed Biologics interviewed by Business Focus Magazine: Lifesaving Science- AS A LEADING BIOPHARMACEUTICAL INNOVATOR, DEVELOPER AND MANUFACTURER, TAIMED BIOLOGICS IS RESHAPING
2025/10/22
TaiMed Biologics (4147) Presents Promising Results on Novel CD4⁺ Targeted Antibody-Drug Conjugate (ADC) for HIV Treatment at ID Week 2025
2025/10/20
Saudi Food and Drug Authority (SFDA) Grants Orphan Drug Designation to TaiMed Biologics' HIV treatment, Trogarzo - a Monoclonal Antibody for Multidrug-Resistant HIV-1 Infection
2025/09/08
TaiMed Biologics (4147) Invited to Share Antibody Therapeutics R&D and Manufacturing Strategies at Biologics CDMO Asia 2025
2025/07/25
TaiMed Biologics (4147) Invited to Share Key Business Priorities and Strategic Plan at the 2025 Taiwan Biotech Industry Summit Forum
2025/07/15
TaiMed Biologics (4147) invited to participate in the Taiwan Biotech Industry Summit Forum
2025/07/04
TaiMed Biologics(4147) Confirms Continuity of Trogarzo® Partnership Amidst Future Pak Acquisition of Theratechnologies
2025/06/30
TaiMed Biologics (4147) has been selected to Present Research on Novel CD4+ Cell-Targeting Antibody-Drug Conjugates for HIV Treatment at ID Week 2025
2025/06/22
TaiMed Biologics has initiated Phase IIb Clinical Study Protocol Preparation of Long-Acting HIV Therapy TMB-365/380 to the U.S. FDA
2025/06/10
TaiMed Biologics Signs MOU with NTU School of Pharmacy to Launch Internship and Talent Development Program
2025/04/30
TaiMed Biologics Signed CDMO Service Agreement with U.S. Client, Adding Growth Momentum to Operations